Effects of bezafibrate in patients with combined hyperlipidemia
Vílchez Joya, R.; Escobar Jiménez, F.; Campos, M.M.; Torres, E.; Orduña, R.; Cabrera, J.; Núñez, J.
Medicina Clinica 86(5): 190-194
1986
ISSN/ISBN: 0025-7753 PMID: 3959651 Document Number: 284749
The short-term lipid-lowering activity of bezafibrate was studied in 19 patients with diabetes mellitus and in 25 atherosclerotic patients with normal glucose tolerance. After management with diet during 3 months, 200 mg of bezafibrate were administered 3 times a day. In diabetic patients, whose Hb A1c at the end of the study was 7.6%, both cholesterol and triglycerides were reduced after 6 months of therapy by 29.38%, respectively, with a 16.05% increase in HDL-cholesterol. In atherosclerotic patients the reduction of cholesterol was 25.13% of the initial value and that of triglycerides was 47.35%, with a 13.43% increase in HDL-cholesterol values. In both groups the increase in HDL-cholesterol values reached significance only after the third month. After 6 months of therapy, the HDL-cholesterol/cholesterol ratio (the so-called atherogenic risk) was modified by 60% and 45% in each group of patients, respectively. A strong lipid-lowering effect of bezafibrate was shown after the third month of therapy, with reductions in serum cholesterol and triglyceride values; these reductions suggest, in the absence of other risk factors in the study populations, a direct effect of the drug.